ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
At the 2025 IEEE International Electron Devices Meeting (IEDM), research centre Imec is presenting breakthrough performance of p-type FETs with monolayer WSe 2 channels, and improved fab-compatible ...
Who needs JavaScript? Security researcher Lyra Rebane has devised a novel clickjacking attack that relies on Scalable Vector ...
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...
Investing.com -- Senti Biosciences (NASDAQ:SNTI) stock surged 29% after the company reported positive clinical trial results for its cancer therapy SENTI-202 and received FDA Regenerative Medicine ...
Applied Materials' AI-fueled gains lift shares 56% this year, but export limits, rivals and valuation cloud the near-term outlook.
First Spark is a deep tech venture capital fund investing in breakthrough technologies. Peter said that he specializes in investments in AI, biotech, and quantum technologies. Each panelist gave a ...
Deep vertical holes and re-entrant features challenge the best metrology methods.
Senti Biosciences (NASDAQ:SNTI) soared 29% on Tuesday after unveiling encouraging clinical data from its SENTI-202 cancer ...
As of Tuesday, December 09, Senti Biosciences, Inc.’s SNTI share price has surged by 11.51%, which has investors questioning if this is right time to sell.
Smartkem, Inc. (Nasdaq: SMTK), a company developing a new class of organic semiconductor technology, today announced that it has created ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback